Aurobindo Pharma Ltd receives EIR from USFDA classifying Unit IV as 'Voluntary Action Indicated'

The U.S. Food and Drug Administration (FDA) had conducted an inspection at the Unit IV, a Formulation manufacturing facility, of APL Healthcare Limited, a wholly owned subsidiary of the Company, situated at Menakuru Village, Naidupeta Mandal, Tirupati District, Andhra Pradesh, from September 13 to September 19, 2023.

The Unit has now received Establishment Inspection Report classifying the facility as "Voluntary Action Indicated" ("VAI").

Shares of Aurobindo Pharma Limited was last trading in BSE at Rs. 1032.70 as compared to the previous close of Rs. 1021.65. The total number of shares traded during the day was 18714 in over 940 trades.

The stock hit an intraday high of Rs. 1035.00 and intraday low of 1009.55. The net turnover during the day was Rs. 19217795.00.

Source : Equity Bulls

Keywords

AurobindoPharma INE406A01037 APLHealthcare Unit4 FormulationManufacturingFacility EIR VAI